Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04802733 |
|
Recruitment Status : Unknown
Verified May 2022 by BlueRock Therapeutics.
Recruitment status was: Active, not recruiting
First Posted : March 17, 2021
Last Update Posted : June 2, 2022
|
Sponsor:
BlueRock Therapeutics
Collaborator:
Memorial Sloan Kettering Cancer Center
Information provided by (Responsible Party):
BlueRock Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | May 2023 |
| Estimated Study Completion Date : | May 2024 |